Medaxone 1 g

A III generation cephalosporin antibiotic for parenteral use. It has bactericidal action, inhibits cell membrane synthesis, in vitro suppresses growth of most gram-positive and gram-negative microorganisms. Ceftriaxone is resistant to β-lactamases (both penicillinase and cephalosporinase produced by most Gram-positive and Gram-negative bacteria).

The drug is active against Gram-positive microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus A (Streptococcus pyogenes), Streptococcus V (Streptococcus agalactiae), Streptococcus viridans, Streptococcus bovis.

The drug is active against Gram-negative microorganisms:Aeromonas spp., Alcaligenes spp., Branhamella catarrhalis, Citrobacter spp, Enterobacter spp. (some strains are resistant), Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebssiella spp. (including Klebssiella pneumoniae), Moraxella spp, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Plesiomonas shigelloides, Proteus mirabilis, Proteus vulgaris, Providencia spp., Pseudomonas aeruginosa (some strains are resistant), Salmonella spp., Vibrio spp., (incl. Vibrio cholerae), Yersinia spp., (incl. Yersinia Enterocolitica).

Many strains of the listed gram-negative microorganisms, which in the presence of other antibiotics, such as penicillins, first generation cephalosporins and aminoglycosides, reproduce stably, are sensitive to ceftriaxone.

Treponema pallidum is sensitive to ceftriaxone both in vitro and in animal experiments. Clinical data in primary and secondary syphilis show good efficacy of ceftriaxone.

The drug is active against anaerobic microorganisms: Bacteroides spp. (including some strains of Bacteroides fragilis), Clostridium spp. (including Clostridium difficile), Fusobacterium spp. (except Fusobacterium mostiferum, Fusobacterium varium), Peptococcus spp, Peptostreptococcus spp.

The following are resistant to the drug: Staphylococcus strains resistant to methicillin; most strains of enterococci (for example, Streptococcus faecalis); some strains of many Bacteroides (for example, Bacteroides fragilis) that produce β-lactamase (to determine the sensitivity of microorganisms it is necessary to use disks containing ceftriaxone, because it is shown in vitro.because it has been shown that in vitro certain strains of pathogens can be resistant to classical cephalosporins).

Indications

Infectious and inflammatory diseases caused by microorganisms sensitive to the drug:

sepsis;
meningitis;
abdominal infections (peritonitis, inflammatory diseases of the gastrointestinal tract, biliary tract);
bone and joint infections;
skin and soft tissue infections;
kidney and urinary tract infections;
respiratory tract infections (including pneumonia);
ENT infections;
genital infections (including gonorrhea);
infections in patients with reduced immunity.

Prevention of infections in the postoperative period.

Pharmacological effect

III generation cephalosporin antibiotic for parenteral use. It has a bactericidal effect, inhibits the synthesis of the cell membrane, and in vitro inhibits the growth of most gram-positive and gram-negative microorganisms. Ceftriaxone is resistant to β-lactamases (both penicillinase and cephalosporinase, produced by most gram-positive and gram-negative bacteria).

The drug is active against gram-positive microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus A (Streptococcus pyogenes), Streptococcus V (Streptococcus agalactiae), Streptococcus viridans, Streptococcus bovis.

The drug is active against gram-negative microorganisms: Aeromonas spp., Alcaligenes spp., Branhamella catarrhalis, Citrobacter spp., Enterobacter spp. (some strains are resistant), Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebssiella spp. (including Klebssiella pneumoniae), Moraxella spp., Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Plesiomonas shigelloides, Proteus mirabilis, Proteus vulgaris, Providencia spp., Pseudomonas aeruginosa (some strains are resistant), Salmonella spp., Vibrio spp., (including Vibrio cholerae), Yersinia spp., (including Yersinia Enterocolitica).

Many strains of the listed gram-negative microorganisms, which multiply stably in the presence of other antibiotics, for example, penicillins, first-generation cephalosporins and aminoglycosides, are sensitive to ceftriaxone.

Treponema pallidum is sensitive to ceftriaxone both in vitro and in animal experiments. According to clinical data, ceftriaxone has good efficacy in primary and secondary syphilis.

The drug is active against anaerobic microorganisms: Bacteroides spp. (including some strains of Bacteroides fragilis), Clostridium spp. (including Clostridium difficile), Fusobacterium spp. (except Fusobacterium mostiferum, Fusobacterium varium), Peptococcus spp., Peptostreptococcus spp.

The following are resistant to the drug: Staphylococcus strains resistant to methicillin; most strains of enterococci (for example, Streptococcus faecalis); some strains of many Bacteroides (for example, Bacteroides fragilis) that produce β-lactamase (to determine the sensitivity of microorganisms, it is necessary to use disks containing ceftriaxone, since it has been shown that in vitro certain strains of pathogens can be resistant to classical cephalosporins).

Special instructions

In case of simultaneous severe renal and liver failure, the plasma concentration of the drug should be regularly determined.
In patients on hemodialysis, it is necessary to monitor the concentration of ceftriaxone in plasma, because they may have a reduced rate of elimination.

Active ingredient

Ceftriaxone

Composition

1 bottle contains:

Contraindications

Hypersensitivity to cephalosporins and penicillins.

Side Effects

Allergic reactions: urticaria, chills or fever, rash, itching, rarely – bronchospasm, eosinophilia, polymorphic erythema, exudative (including Stevens-Johnson syndrome), serum sickness, angioedema, anaphylactic shock.

Interaction

Combination therapy

Overdose

Excessively high plasma concentrations of ceftriaxone cannot be lowered by hemodialysis or peritoneal dialysis.

Storage conditions

List B. In a dry place, protected from light, at a temperature not exceeding 25°C.

Shelf life

2 years.

Manufacturer

Medokemi Ltd, Cyprus